Rosetta Genomics Ltd.
ROSGQ · OTC
6/30/2017 | 12/31/2016 | 9/30/2016 | 6/30/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.25 | -0.77 | 1.13 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -1.34 | -21.05 | -51.40 | -86.05 |
| Quality | ||||
| ROIC | -38.05% | -51.77% | -43.51% | -25.48% |
| Gross Margin | 34.60% | 0.84% | 18.64% | -22.77% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 70.10% | 105.55% | 185.17% | 234.22% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.82 | 0.48 | 1.34 | 2.43 |
| Interest Coverage | 0.00 | -7.69 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -61.76 | 59.45 | 93.32 | 743.65 |